

ADNI biostatistics conference call  
3 November 2009

Present on call: Danielle Harvey, Laurel Beckett, David Shera, Kisook Yoo, Niclas Sjogren, David Verbel, Hao Zhang, Fred Immerman, John Kornak, Thomas Kelleher.

Update on ADNI-1 analysis: We completed the ADNI analyses and preparations for ADNI-2 submission. We did a huge amount of analysis in a very short time and prepared many reports, then summaries of the reports, then summaries of the summaries. We also wrote a biostat core, and contributed to all the other cores for the ADNI-2 proposal. Much work, and many thanks for the feedback and help from the group.

We now have official word that the ADNI-GO is funded, and we are already starting on this project. It is only funded for two years so the timeline is tight to get started and then get papers out. ADNI-2 would overlap with GO in the last year; we would still have plenty of biostat funding as there is a lot of work to do.

Our plans for the next few months are to emphasize getting papers out based on our biostatistical work, and in collaboration with others, following up on the analyses we did for ADNI-1 and renewal. Then we'll have a big push for ADNI-GO analysis, no doubt.

Update on papers: Danielle has submitted the paper on methods for comparison of ADNI markers. She got 4 reviews, 2 very positive and 2 not so much. The paper with reworking should be able to get accepted though. Then she will pursue some applications. One is the 1.5T vs 3T, which is of interest to the MRI community. One paper is out but focused on their method, not a comprehensive comparison. She also wants to look across MRI labs and across PET labs, working with the PI's of those Cores and labs.

Laurel and Danielle are going to pursue a paper on the normals, building on the work that we did starting in Spring. We discussed possible overlap of this paper with the one that Mike is starting, and he thinks there is minimal overlap. We will keep people posted. We believe Mike Donohue and Anthony Gamst are working on one or more papers reflecting their work on clinical trials design and the impact of biomarkers. We will try to get a list of other papers underway.

John Kornak reports that his 3% may be coming to an end so he is not sure of his role in the future.

The next scheduled call is 1 December at 10 AM Pacific time.